In line with its pro-oncogenic functions in HCC, novel specific inhibitors of SIRT7 demonstrated capacity to retard growth of liver cancer cells in in vivo, suggesting that targeting SIRT7 may represent an efficient therapeutic target for this devastating malignancy [63]. The gene discussed is SIRT7; the disease is hepatocellular carcinoma.